Image

Global Gonorrhea Testing Market– Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Aug 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Healthcare
  • Upcoming Report
  • Aug 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Gonorrhea Testing Market, By Test Type (Nucleic Acid Amplification, Gram Stain, Enzyme-linked immunosorbent assay, Gonorrhea Culture and Rapid Test), Sample Type (Blood, Lymph Fluid, Urine, Throat Swab and Penis/Vaginal Swab), End-User (Hospitals, Pathology Lab and Point of Care Testing) – Industry Trends and Forecast to 2029.

Gonorrhea Testing Market

Gonorrhea Testing Market Analysis and Size

According to the CDC, the most frequent infectious disease among young people is gonorrhea which causes 820,000 new cases in the United States each year. 70% of the population among these 820,000 new cases is anticipated to be between the ages of 15 and 24. According to the CDC, women over 25 are more likely to contract gonorrhea. Unprotected intercourse, having several sex partners, and having oral or anal sex with a person with an STI are all risk factors for gonorrhea.

Data Bridge Market Research analyses that the gonorrhea testing market which was USD 7.5 billion in 2021, would rocket up to USD 13.88 billion by 2029, and is expected to undergo a CAGR of 8.00% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Gonorrhea Testing Market Scope and Segmentation      

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Test Type (Nucleic Acid Amplification, Gram Stain, Enzyme-linked immunosorbent assay, Gonorrhea Culture and Rapid Test), Sample Type (Blood, Lymph Fluid, Urine, Throat Swab and Penis/Vaginal Swab), End-User (Hospitals, Pathology Lab and Point of Care Testing)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Abbott (U.S.), Aposcience (Austria), BD (U.S.), Biocartis (Belgium), bioMérieux (France), Bio-Rad Laboratories, Inc (U.S.), Cepheid (U.S.), Danaher (U.S.), DiaSorin S.p.A (Italy), GenMark Diagnostics, Inc. (U.S.), Hologic Inc. (U.S.), OraSure Technologies Inc. (U.S.), Qualigen Technologies Inc. (U.S.), Quidel Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc (U.S.), MedMira Inc. (Canada)

Market Opportunities

  • To develop exponentially as more people engage in numerous sex relationships
  • To raise public awareness of the problem

Market Definition

Both sexes are susceptible to the sexually transmitted disease gonorrhea brought by the bacterium Neisseria gonorrhea. It is a widespread infection, particularly among teenagers between the ages of 14 and 15. Men can get testicular enlargement, painful urination, and pus discharge from gonorrhea. Painful urination, profuse vaginal discharge, and stomach ache are symptoms in women. Women and men get these diseases at different rates. The onset of symptoms varies between 2 and 14 days for males and 7 and 21 days for women.

Gonorrhea Testing Market Dynamics

Drivers

  • Increase in number of people engaged in multiple sex relationship

The market for gonorrhea testing is anticipated to experience exponential expansion as a result of the rising number of people engaging in multiple sex relationships and changing lifestyles. According to the CDC, gonorrhea infection/bacteria are becoming more resistant to patient strains, which further increases the need for gonorrhea diagnostic tests.

  • Rise in sexually transmitted diseases (STDs)

The rising prevalence of STDs and expanding government campaigns to raise public awareness of the problem would spur market expansion. Additionally, throughout the forecast period, the gonorrhea tseting market is anticipated to increase as a result of government reforms introduced to strengthen the healthcare infrastructure, with a greater emphasis on emerging nations.

Opportunities

The gonorrhea testing market is anticipated to develop exponentially as more people engage in numerous sex relationships and as lifestyles change, both of which will accelerate the market's expansion. According to the CDC, gonorrhea bacteria and infection are becoming more difficult for people to contract, which is driving up market demand.

Restraints/Challenges

  • High cost

High cost of test will act as a restraint, and further will challenge the growth of gonorrhea testing market in the forecast period of 2022-2029. However, the high price of the gonorrhea diagnostic test is expected to limit market expansion to some extent.

This gonorrhea testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on gonorrhea testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Gonorrhea Testing Market

An unprecedented global public health threat, the COVID-19 pandemic is expected to have a detrimental effect on the Gonorrhea testing market. The prevalence of sexually transmitted infections was high prior to the pandemic, although it has since dropped as a result of STD testing. Due to difficulties in health care and services for testing for sexually transmitted infections during the early months of the COVID-19 epidemic, there were fewer reports of STIs. In order to maintain the supply of personal protective equipment and lower the exposure risks for patients and clinical personnel, preventive services were reduced, and many non-urgent visits were severely postponed or switched to virtual platforms.

Global Gonorrhea Testing Market Scope

The gonorrhea testing market is segmented on the basis of type, sample type and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

Sample Type

  • Blood
  •  Lymph Fluid
  •  Urine
  • Throat Swab
  • Penis/Vaginal Swab

End-User

  • Hospitals
  • Pathology Lab
  • Point of Care Testing

Gonorrhea Testing Market Regional Analysis/Insights

The gonorrhea testing market is analysed and market size insights and trends are provided by country, type, sample type and end-user as referenced above.

The countries covered in the gonorrhea testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market due to large number of care test and high awareness among people regarding sexually transmitted diseases.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the rising health awareness among the people.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Gonorrhea Testing Market Share Analysis

The gonorrhea testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to gonorrhea testing market.

Some of the major players operating in the gonorrhea testing market are:

  • Abbott (U.S.)
  • Aposcience (Austria)
  • BD (U.S.)
  • Biocartis (Belgium)
  • bioMérieux (France)
  • Bio-Rad Laboratories Inc (U.S.)
  • Cepheid (U.S.)
  • Danaher (U.S.)
  • DiaSorin S.p.A (Italy)
  • GenMark Diagnostics Inc. (U.S.)
  • Hologic Inc. (U.S.)
  • OraSure Technologies Inc. (U.S.)
  • Qualigen Technologies Inc. (U.S.)
  • Quidel Corporation (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Thermo Fisher Scientific Inc (U.S.)
  • MedMira Inc. (Canada)


SKU-
Why Choose Us


Frequently Asked Questions

The gonorrhea testing market value is projected USD 13.88 billion by 2029.
The gonorrhea testing market is projected to grow at a CAGR of 8.00% during the forecast period of 2022-2029.
The major players operating in the Gonorrhea Testing Market are Abbott (U.S.), Aposcience (Austria), BD (U.S.), Biocartis (Belgium), bioMérieux (France), Bio-Rad Laboratories, Inc (U.S.), Cepheid (U.S.), Danaher (U.S.), DiaSorin S.p.A (Italy), GenMark Diagnostics, Inc. (U.S.), Hologic Inc. (U.S.), OraSure Technologies Inc. (U.S.), Qualigen Technologies Inc. (U.S.), Quidel Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc (U.S.), MedMira Inc. (Canada).
The major countries covered in the Gonorrhea Testing Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.